Group 1 - QuinStreet (QNST) shares have increased by 8.1% over the past four weeks, closing at $16.06, with a mean price target of $28.40 indicating a potential upside of 76.8% [1] - The mean estimate consists of five short-term price targets with a standard deviation of $5.90, where the lowest estimate of $19 suggests an 18.3% increase, and the highest estimate of $35 indicates a potential surge of 117.9% [2] - Analysts show a consensus that QNST will report better earnings than previously estimated, with a positive trend in earnings estimate revisions correlating with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for QNST has increased by 31.4% due to two estimates moving higher and one moving lower over the last 30 days [12] - QNST holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside [13] - While price targets can be misleading, the direction indicated by the consensus price target may serve as a useful guide for potential price movements [10][13]

Group 1 - Silence Therapeutics PLC Sponsored ADR (SLN) shares have increased by 52% in the past four weeks, closing at $5.41, with a mean price target of $35.50 indicating a potential upside of 556.2% [1] - The mean estimate consists of six short-term price targets with a standard deviation of $23.86, where the lowest estimate is $3 (44.6% decline) and the highest is $75 (1286.3% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements [11] Group 2 - The Zacks Consensus Estimate for SLN has increased by 4.4% due to one upward revision in the last 30 days, with no negative revisions [12] - SLN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the stock's potential gain, it suggests a positive direction for price movement [13]

Core Viewpoint - Agenus (AGEN) shares have increased by 68.4% over the past four weeks, closing at $5, with a mean price target of $6.33 indicating a potential upside of 26.6% [1] Price Targets and Analyst Estimates - The mean estimate consists of three short-term price targets with a standard deviation of $2.08, where the lowest estimate of $4 suggests a 20% decline, while the highest target of $8 indicates a potential 60% increase [2] - A low standard deviation among price targets suggests a strong agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Optimism - Analysts show strong agreement in revising earnings per share (EPS) estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, three EPS estimates for the current year have been revised upward, leading to a 52.4% increase in the Zacks Consensus Estimate [12] Zacks Rank and Investment Potential - Agenus holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]

Group 1 - Energy Transfer LP (ET) closed at $17.90, with a 13.2% gain over the past four weeks, and a mean price target of $22.93 suggests a 28.1% upside potential [1] - The average of 14 short-term price targets ranges from $19 to $26, with a standard deviation of $1.94, indicating variability in estimates; the lowest estimate suggests a 6.2% increase, while the highest indicates a 45.3% upside [2] - Analysts show strong agreement on ET's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for ET's current year earnings has increased by 2.6% over the past month, with four estimates revised higher and no negative revisions [12] - ET holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13] - While consensus price targets may not be reliable for predicting exact gains, they can provide a directional guide for price movement [13]

Shares of Knot Offshore (KNOP) have gained 0.3% over the past four weeks to close the last trading session at $6.39, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $13.17 indicates a potential upside of 106.1%.The average comprises three short-term price targets ranging from a low of $12 to a high of $15, with a standard deviation of $1.61. While the lowest estimate indicates a ...

Core Viewpoint - Intellia Therapeutics, Inc. (NTLA) has seen a 6.1% increase in share price over the past four weeks, closing at $7.69, with analysts suggesting a potential upside of 398.3% based on a mean price target of $38.32 [1] Price Targets and Analyst Consensus - The average of 25 short-term price targets ranges from a low of $7 to a high of $106, with a standard deviation of $24.94, indicating variability in estimates [2] - The lowest estimate suggests a 9% decline from the current price, while the highest indicates a potential upside of 1278.4% [2] - Analysts' price targets should be approached with caution, as their reliability has been questioned [3][7] Earnings Estimates and Market Sentiment - Analysts are optimistic about NTLA's earnings prospects, with a consensus indicating better-than-previously estimated earnings, which historically correlates with stock price movements [4][11] - Over the last 30 days, 10 earnings estimates have been revised upward, resulting in an 8.3% increase in the Zacks Consensus Estimate for the current year [12] - NTLA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for upside [13]

Group 1 - Mind Medicine (MindMed) Inc. (MNMD) closed at $7.26, with a 4.8% gain over the past four weeks, and a mean price target of $24.50 suggests a 237.5% upside potential [1] - The mean estimate includes 10 short-term price targets with a standard deviation of $12.13, indicating variability; the lowest estimate of $16 suggests a 120.4% increase, while the highest estimate of $55 indicates a 657.6% potential surge [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases, as the Zacks Consensus Estimate for the current year has increased by 4% over the past month [4][12] Group 2 - MNMD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a solid potential upside [13] - The clustering of price targets with a low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement direction [9] - While price targets are often viewed skeptically, the direction they imply can serve as a useful guide for further research into the stock's potential [10]

Core Viewpoint - Ooma (OOMA) has shown an 8.8% increase in stock price over the past four weeks, with a mean price target of $18.30 indicating a potential upside of 34.1% from the current price of $13.65 [1] Price Targets and Analyst Estimates - The mean estimate consists of five short-term price targets with a standard deviation of $1.10, where the lowest estimate is $17 (24.5% increase) and the highest is $20 (46.5% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about Ooma's earnings prospects, with a positive trend in earnings estimate revisions correlating with potential stock price increases [4][11] - The Zacks Consensus Estimate for the current year has risen by 6.2% over the past month, with three estimates increasing and no negative revisions [12] Zacks Rank and Investment Potential - Ooma holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate the direction of price movement [13]

Group 1 - American Superconductor (AMSC) shares have increased by 35.4% in the past four weeks, closing at $27.38, with a mean price target of $39 indicating a potential upside of 42.4% [1] - The average price targets from analysts range from a low of $38 to a high of $40, with a standard deviation of $1, suggesting a strong agreement among analysts regarding the stock's potential movement [2] - Analysts are optimistic about AMSC's earnings prospects, as indicated by positive revisions in earnings estimates, which historically correlate with stock price movements [4][9] Group 2 - The Zacks Consensus Estimate for AMSC has increased by 2.5% due to two upward revisions in earnings estimates over the last 30 days, with no negative revisions [10] - AMSC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [11] - While price targets may not be entirely reliable, the direction they imply can serve as a useful guide for investors [11]

Core Viewpoint - CryoPort, Inc. (CYRX) has seen a 7.3% increase in share price over the past four weeks, closing at $6.03, with a potential upside indicated by Wall Street analysts' mean price target of $10.94, suggesting an 81.4% increase [1][11]. Price Targets and Analyst Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $3.05, indicating variability among analysts; the lowest estimate is $6.50 (7.8% increase), while the highest is $15 (148.8% increase) [2][9]. - Analysts' consensus on price targets is often questioned, as they may not accurately reflect future stock prices; empirical research suggests that price targets can mislead investors [3][7]. - Despite skepticism around price targets, a low standard deviation among estimates indicates strong agreement among analysts regarding the stock's price direction [9][10]. Earnings Estimates and Market Sentiment - Analysts are optimistic about CYRX's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlate with stock price movements [4][11]. - The Zacks Consensus Estimate for the current year has risen by 20.8% over the past month, with four estimates increasing and no negative revisions [12]. - CYRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for near-term upside [13].